Results 241 to 250 of about 106,022 (294)

The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)

Expert Opinion on Drug Safety, 2023
Introduction Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide.
R. McIntyre, R. Mansur, J. Rosenblat, A. Kwan   +3 more
semanticscholar   +1 more source

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources

Comparative effectiveness of glucagon‐like peptide‐1 receptor agonists for the management of obesity in adults without diabetes: A network meta‐analysis of randomized clinical trials

Obesity Reviews, 2022
Tirzepatide is a new glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) that has shown promising results for weight loss. A Bayesian network meta‐analysis was conducted to compare the efficacy and safety of GLP‐1RAs for obesity management.
Omar S. Alkhezi, A. Alahmed, Osamah M. Alfayez, Osama A Alzuman, Abdulaali R. Almutairi, O. Almohammed   +5 more
semanticscholar   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry

Journal of Clinical Psychopharmacology
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. Finally, the pharmacological treatment of obesity seems to have a breakthrough after decades of setbacks, with previous weight ...
Himmerich, Hubertus, McElroy, Susan L
openaire   +3 more sources

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes

Annals of Internal Medicine
BACKGROUND Recent randomized controlled trials (RCTs) have investigated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual or triple co-agonists for weight loss among adults with overweight or obesity and without diabetes. PURPOSE To assess
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, Michael A Tsoukas, O. Yu, Tricia M. Peters, Mark J. Eisenberg   +6 more
semanticscholar   +1 more source

Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement.

British Journal of Anaesthesia
The perioperative management of patients using glucagon-like peptide 1 receptor agonists remains a topic of debate. While several multisociety statements have been published recently, the recommendations vary significantly in terms of medication ...
A. Oprea, Laura J. Ostapenko, BobbieJean Sweitzer, Angela Selzer, Joan M. Irizarry-Alvarado, M. H. Hurtado Andrade, Carlos E. Mendez, Kristen D. Kelley, E. Stewart, Claudia R. Fernandez Robles, R. Chadha, Michael Camilleri, R. Mathur, Guillermo E. Umpierrez, David L. Hepner   +14 more
semanticscholar   +1 more source

Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

Metabolism: Clinical and Experimental
BACKGROUND AND AIMS While glucagon-like peptide-1 receptor agonists (GLP-1RAs) effectively reduce body weight, their impact on lean mass remains uncertain.
P. Karakasis, Dimitrios Patoulias, N. Fragakis, Christos S. Mantzoros   +3 more
semanticscholar   +1 more source

Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysis

Obesity, 2022
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists recently demonstrated 15% to 20% weight loss in adults with obesity, a range which has previously been achieved only with bariatric surgery.
Shohinee Sarma, Patricia Palcu
semanticscholar   +1 more source

Cardioprotective Effects of Glucagon-Like Peptide 1 Receptor Agonists

Kardiologiia, 2014
In this paper we discuss pathogenetic mechanisms of cardiovascular risk reduction in patients with type 2 diabetes mellitus by glucagon-like peptide 1 (GLP-1) receptor agonists. Results of experimental studies and randomized clinical studies are presented, and perspectives for using GLP-1 agonists in patients with diabetic cardiovascular complications ...
A S, Ametov, L L, Kamynina, Z G, Akhmedova   +2 more
openaire   +2 more sources

Glucagon-like peptide-1 receptor agonists and the eye

Current Opinion in Ophthalmology
Purpose of review Glucagon-like peptide-1 receptor agonists (GLP-1RA) have gained popularity as an antidiabetic and weight loss agent with protective cardiovascular outcomes, but attention to the potential ocular side effects has grown.
David L, Zhang, Avni P, Finn
openaire   +2 more sources